Tirzepatide cost per month: what it actually runs in 2026

Last updated 2026-07-30

how much does tirzepatide cost per month, really

The honest answer has three different numbers depending on whether you have insurance, whether you qualify for a manufacturer discount, and whether you're on brand or compounded product. Eli Lilly lists Zepbound (approved for chronic weight management) and Mounjaro (approved for type 2 diabetes) at the same list price of $1,086.37 per 4-week supply, regardless of dose, according to Lilly's own pricing page. That's the sticker price nobody actually wants to pay, and increasingly, few people do. With commercial insurance that covers the drug, copays commonly land between $25 and $150 a month when combined with a Lilly savings card. Without insurance coverage for the drug class, Lilly's self-pay program through LillyDirect prices single-dose vials of Zepbound at $349 to $499 a month for the 2.5 mg and 5 mg starter doses, and up to $649 for higher doses, per Lilly's published vial pricing. Compounded tirzepatide, where still legally available, has historically run $150 to $400 a month, though that market has narrowed sharply since 2024. So when someone asks 'what does tirzepatide cost per month,' the real answer is: it depends entirely on which of four or five payment paths you're on. We'll walk through each.

what is the list price of zepbound and mounjaro without insurance

Full list price (also called wholesale acquisition cost) for both Zepbound and Mounjaro is $1,086.37 for a 28-day supply, at every dose from 2.5 mg up to the 15 mg maximum, according to Lilly's pricing disclosure. That number surprises people. Dose doesn't change the price at the pharmacy counter because Lilly prices by box, not by milligram. At list price, a year of treatment runs roughly $13,000, before any rebates a pharmacy benefit manager might negotiate behind the scenes. Almost nobody with insurance pays this number. It matters mostly as the baseline that cash-pay and coinsurance percentages get calculated from, and it's the number you'll see quoted in news coverage of GLP-1 drug prices. Mounjaro's FDA approval covers type 2 diabetes as an adjunct to diet and exercise, based on the SURPASS trial program. Zepbound's approval covers chronic weight management in adults with obesity or overweight with a weight-related condition, based on the SURMOUNT trials. Same molecule, same list price, different approved indication and different insurance pathway, which is often the bigger driver of your actual cost than the price tag itself.

how much is tirzepatide with insurance

This is where the range gets wide. Insurance coverage for GLP-1/GIP drugs varies enormously by employer plan, state Medicaid program, and whether the drug is prescribed for diabetes versus weight loss. For Mounjaro (diabetes), most commercial plans that cover it place it on a mid-to-high tier, with copays commonly $25 to $100 a month when a manufacturer copay card applies. Lilly's Mounjaro Savings Card has historically let eligible commercially-insured patients pay as little as $25 for a 1 to 3 month prescription, capped by an annual maximum, per Lilly's savings card terms. For Zepbound (weight loss), coverage is spottier. Many employer plans exclude anti-obesity medications entirely; this is legal because obesity drug coverage isn't a mandated essential health benefit under the ACA in most states. If your plan does cover Zepbound, the Zepbound Savings Card has offered eligible commercially-insured patients pricing as low as $25 for a 1 or 3-month supply, with a separate, less generous cash-pay savings tier for people whose insurance doesn't cover it, according to Lilly's Zepbound savings program page. Medicare Part D does not cover Zepbound for weight loss because Medicare is statutorily barred from covering drugs used for weight loss under the Medicare Modernization Act's exclusion list, per CMS guidance on Part D excluded drugs ^[1]. Medicare Part D can cover Mounjaro when prescribed for type 2 diabetes, subject to your plan's formulary tier and deductible. Medicaid coverage varies state by state and changes often. Some states cover Zepbound or Wegovy for obesity, many don't. Check your specific state Medicaid formulary rather than assuming.

what does compounded tirzepatide cost per month

Compounded tirzepatide, made by a licensed 503A or 503B pharmacy rather than by Lilly, has typically cost $150 to $400 a month, well below brand list price. That's the number that drove a lot of the compounding boom in 2023 and 2024. But the legal landscape shifted. The FDA removed tirzepatide from its drug shortage list in December 2024, stating the agency had 'confirmed with the manufacturer, Eli Lilly and Company... that the shortage of tirzepatide products... is resolved' ^[2]. Compounding pharmacies are generally only permitted to make copies of a commercially available drug during a declared shortage, or for a patient-specific medical need that the FDA-approved product can't meet (a documented allergy to an inactive ingredient, for instance). After the shortage ended, large-scale mass compounding of tirzepatide became legally shakier, and Lilly pursued legal action against compounders and telehealth platforms it viewed as still selling unauthorized copies. Some legitimate 503A pharmacies still compound tirzepatide for patients with a documented clinical need under a valid prescription, at similar price points, but the broad 'cheap tirzepatide for everyone' market that existed in 2023 to 2024 has shrunk considerably. If you're offered compounded tirzepatide today, ask directly which category it falls under and whether the pharmacy is a licensed 503A or FDA-registered 503B outsourcing facility. That single question separates legitimate compounding from the gray-market vials that have shown up in FDA warning letters. For a broader look at whether compounded or brand product makes sense for your situation, see tirzepatide pros and cons.

why is the price the same at every dose

Lilly prices Zepbound and Mounjaro per box, not per milligram, so the 2.5 mg starter dose and the 15 mg maximum dose both list at $1,086.37 for a 4-week supply. This confuses a lot of new patients who assume cost scales with dose the way it might for a generic tablet. The practical upshot: once you're covered by insurance or a savings card at a flat copay, moving up through the dose-escalation schedule (the SURMOUNT trials used 2.5 mg, 5 mg, 10 mg, 15 mg steps at 4-week intervals) doesn't cost you more per month. It's one of the few genuine silver linings in tirzepatide pricing. For where you land in that escalation and what to expect, see the tirzepatide results timeline.

how does tirzepatide cost compare to semaglutide (wegovy, ozempic)

Both drug families list in a similar range, but head-to-head trial data suggests tirzepatide may deliver more weight loss per dollar for people who respond to it. Wegovy (semaglutide for weight loss) lists at $1,349.02 for a 28-day supply per Novo Nordisk's pricing page ^[3], somewhat higher than Zepbound's $1,086.37. Ozempic (semaglutide for diabetes) lists around $997.58 per Novo Nordisk pricing ^[3] as well, though these figures shift periodically and should be checked against current manufacturer pages. On efficacy, the SURMOUNT-5 head-to-head trial (NCT05822830) compared tirzepatide directly against semaglutide in adults with obesity or overweight, and found tirzepatide produced significantly greater mean weight loss than semaglutide at 72 weeks, according to the trial's published results in NEJM ^[4]. That doesn't make tirzepatide 'worth it' for everyone at a higher net cost after insurance, but it's the relevant comparison if you're choosing between the two purely on a cost-per-pound-lost basis. For a broader comparison across the whole GLP-1 class, this hub covers dosing separately; see also is tirzepatide worth it for the fuller cost-versus-benefit picture. | Drug | Brand | List price (28-day) | Indication |

does the tirzepatide savings card actually save you money

Yes, if you have commercial insurance that covers the drug class at all, even partially. No, or barely, if you're fully uninsured for it. Lilly's savings cards for both Zepbound and Mounjaro are structured for commercially-insured patients: they cap out-of-pocket cost per fill but generally require you to have some form of private insurance, and they explicitly exclude government insurance beneficiaries (Medicare, Medicaid, Tricare) per the card terms published by Lilly. If your insurance denies coverage for the drug outright, the savings card often can't be applied the same way, and Lilly instead points self-pay patients to its LillyDirect vial program at $349 to $649 a month. Read the fine print on eligibility and annual maximum benefit before assuming the advertised '$25' price applies to you. It's a real discount for the right patient, but it is not a universal cash price.

is there a cheaper single-dose vial option for zepbound

Yes. Lilly sells Zepbound in single-dose vials through its LillyDirect self-pay pharmacy channel at prices below the list price for insured, branded pen prescriptions, specifically for patients paying cash without insurance covering the drug. As of Lilly's published vial pricing, the 2.5 mg and 5 mg starter vials cost $349 a month, the 7.5 mg and 10 mg vials cost $499, and the 12.5 mg and 15 mg vials cost $649. This is meaningfully cheaper than the $1,086.37 list price for the auto-injector pen, though it requires self-injection from a vial with a syringe rather than the pen device, and it's only available direct through Lilly's own channel, not at every retail pharmacy. This vial option is often the most realistic 'affordable brand' path for people whose insurance won't touch weight-loss drugs at all.

how much does a full year of tirzepatide cost

At list price with no discounts, a year of Zepbound or Mounjaro runs about $13,036 (12 times $1,086.37). At the LillyDirect vial cash-pay rate, assuming a typical escalation to a 10 mg or 12.5 mg maintenance dose, expect roughly $5,000 to $7,800 a year. With full insurance coverage and a savings card capping monthly cost around $25 to $50, annual out-of-pocket cost can run under $1,000, though annual savings-card maximums do apply and vary by program. The SURMOUNT-1 trial (NCT04184622), which established Zepbound's weight-loss efficacy, ran 72 weeks, meaning most people evaluating whether the drug 'works' for them are looking at well over a year of treatment before judging final results, and clinical guidance generally treats tirzepatide as a long-term or indefinite therapy for chronic weight management, similar to how you'd treat hypertension medication. Budget accordingly rather than assuming a short course. For what results actually look like over that stretch, see the tirzepatide before and after breakdown and the tirzepatide success rate data.

what happens to the cost if you stop and restart, or if you need to change doses

Cost doesn't scale with dose at the pharmacy (see above), but stopping and restarting can cost you in a different way: most patients need to re-titrate from a low starting dose if they've been off the drug for an extended period, per the same dose-escalation logic used in the SURMOUNT trials, and weight regain after stopping is common. A study tracking the SURMOUNT-4 withdrawal cohort found participants who switched from tirzepatide to placebo regained a substantial portion of lost weight during the following year ^[5]. That means the real 'cost' of stopping isn't just a paused subscription. It's often a second round of titration-phase treatment (paid at the same monthly rate) to get back to where you were, plus the psychological cost of regained weight. If cost is forcing intermittent use, it's worth discussing a lower maintenance dose with your prescriber rather than full stop-start cycling, since a lower stable dose may be both cheaper to sustain and more effective than repeated restarts.

are there other real costs beyond the drug itself

Yes, and people frequently underbudget these. Add up: an initial consultation or telehealth visit fee (commonly $0 to $250 depending on whether it's covered by insurance), periodic follow-up visits, and possibly lab work if your provider wants baseline or monitoring bloodwork. Supplies matter too if you're using vials rather than a pre-filled pen: syringes, alcohol wipes, and sharps disposal are typically a small but real recurring cost, usually under $20 a month. And if GI side effects hit hard in the early titration weeks, some patients spend more on electrolyte drinks, fiber supplements, or over-the-counter anti-nausea aids, small dollars but worth mentioning since almost nobody plans for it.

what are the real side effects and risks that come with the cost

Before deciding whether the price is worth paying, know what you're paying for medically. Tirzepatide's most common side effects, per the SURMOUNT-1 and SURPASS trial safety data reviewed in Zepbound's FDA label, are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite, most pronounced during dose escalation and typically easing over time . More serious but less common risks include acute gallbladder disease (cholelithiasis, cholecystitis), which occurred at a higher rate in tirzepatide-treated patients than placebo across trials, and a signal for acute pancreatitis, per the FDA-approved prescribing information . Tirzepatide's label carries a boxed warning for risk of thyroid C-cell tumors, based on findings in rodent studies; it's contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), per the FDA label . This isn't a rare-print footnote, it's a genuine contraindication that rules the drug out entirely for a specific group of patients regardless of budget. None of this is meant to scare you off a drug with real, trial-documented benefit. It's meant to make clear that the monthly cost buys a treatment with a real side-effect profile that needs monitoring, not a supplement you can casually try and stop. Discuss your full medical history, including thyroid and pancreatic history, with a prescriber before starting, regardless of which payment path you're on.

so is tirzepatide worth the cost

That depends on your insurance situation more than on the drug's efficacy, which is well established. The SURMOUNT-1 trial found participants on the highest tirzepatide dose lost an average of 20.9% of body weight at 72 weeks versus 3.1% on placebo, a substantial, clearly statistically significant difference published in the New England Journal of Medicine . If your insurance covers Zepbound or Mounjaro and you qualify for the manufacturer savings card, the effective monthly cost, often $25 to $150, is genuinely reasonable for a drug with this level of trial-backed effect. If you're fully self-pay, the math is harder: $349 to $649 a month through LillyDirect vials, or up to $1,086 for the standard pen, adds up to real money over the 72-plus weeks most people need to see full results. We're a provider-reviewed resource, not a pharmacy, so we won't tell you a specific number is 'worth it' for your budget. What we'd actually suggest: check your specific plan's formulary before assuming coverage either way, ask your prescriber's office to run a benefits check (most telehealth and in-person weight management clinics do this routinely), and compare the LillyDirect vial cash price against any local compounding option, verifying the compounder's license status directly, before committing. If you go the provider-reviewed telehealth route, ask specifically which pharmacy will be filling the prescription and confirm it's a licensed pharmacy partner rather than an unverified overseas supplier.

Frequently asked questions

What is the average cost of tirzepatide per month?

List price for Zepbound and Mounjaro is $1,086.37 for a 28-day supply at every dose ^[1]. With insurance and a manufacturer savings card, many patients pay $25 to $150 a month. Self-pay through Lilly's vial program runs $349 to $649 a month depending on dose ^[2].

Why does tirzepatide cost the same at every dose?

Eli Lilly prices Zepbound and Mounjaro by the box, not by milligram, so the 2.5 mg starting dose and the 15 mg maximum dose both list at $1,086.37 for a 4-week supply ^[1]. Once insured or on a flat-copay savings card, dose escalation doesn't raise your monthly bill.

Does insurance cover tirzepatide for weight loss?

It depends on your plan. Mounjaro (diabetes) is more commonly covered than Zepbound (weight loss), since anti-obesity drug coverage isn't a mandated essential health benefit in most states. Medicare Part D cannot cover Zepbound for weight loss due to a statutory exclusion, though it can cover Mounjaro for diabetes ^[5].

How much is compounded tirzepatide compared to brand?

Compounded tirzepatide has historically cost $150 to $400 a month, well under Zepbound or Mounjaro's $1,086.37 list price. But since the FDA declared the tirzepatide shortage resolved in December 2024, legal mass compounding has narrowed significantly, so availability and legitimacy vary a lot by pharmacy now ^[6].

Can I use the Zepbound or Mounjaro savings card without insurance?

Generally no, the manufacturer savings cards are built for commercially-insured patients and exclude government insurance like Medicare or Medicaid ^[3][4]. If you're uninsured for the drug, Lilly's LillyDirect vial program at $349 to $649 a month is the more relevant self-pay option ^[2].

How much does a year of tirzepatide cost?

At full list price with no discounts, about $13,036 a year (12 x $1,086.37). Through LillyDirect self-pay vials, roughly $5,000 to $7,800 a year depending on maintenance dose. With insurance and a savings card, often under $1,000 a year, subject to an annual program maximum.

Is Zepbound or Mounjaro cheaper?

They're priced identically: $1,086.37 for a 28-day supply for both ^[1]. The difference isn't price, it's indication and insurance pathway; Mounjaro is FDA-approved for type 2 diabetes and tends to get better insurance coverage, while Zepbound is approved for weight management and coverage is more inconsistent.

How does tirzepatide's cost compare to Wegovy or Ozempic?

Wegovy lists at $1,349.02 for 28 days and Ozempic at about $997.58, both per Novo Nordisk's pricing page ^[7], versus $1,086.37 for Zepbound or Mounjaro. In the SURMOUNT-5 head-to-head trial, tirzepatide produced significantly greater weight loss than semaglutide at 72 weeks ^[8].

Are there cheaper vial options for Zepbound?

Yes. Lilly's LillyDirect self-pay channel sells single-dose Zepbound vials at $349 (2.5-5 mg), $499 (7.5-10 mg), or $649 (12.5-15 mg) a month, below the standard pen's list price, for patients paying cash without drug coverage ^[2].

What happens to cost if I stop tirzepatide and restart later?

You'll typically need to re-titrate from a lower dose, meaning another stretch of paying the same monthly price to work back up to your prior maintenance dose. Studies tracking tirzepatide withdrawal found substantial weight regain in the year after stopping, which adds an indirect cost too ^[9].

Does Medicare cover tirzepatide?

Medicare Part D cannot cover Zepbound for weight loss because federal law bars Medicare from covering drugs used for weight loss, per CMS's Part D exclusion guidance ^[5]. Part D can cover Mounjaro when prescribed specifically for type 2 diabetes, subject to your plan's tier and deductible.

What extra costs come with tirzepatide beyond the drug price?

Budget for an initial consultation ($0 to $250 depending on coverage), possible lab work, and if using vials, syringes and sharps disposal (usually under $20 a month). Some patients also spend a little on anti-nausea aids or electrolytes during dose escalation.

What are tirzepatide's serious side effects I should weigh against the cost?

Common effects are GI-related (nausea, diarrhea, vomiting, constipation), most pronounced during dose escalation. More serious risks include gallbladder disease and a pancreatitis signal seen in trials. The FDA label carries a boxed warning for thyroid C-cell tumor risk, and the drug is contraindicated with a personal or family history of MTC or MEN 2 ^[10].

Sources

1. FDA, Tirzepatide Drug Shortage Resolution notice: FDA confirmation that the tirzepatide shortage was resolved as of December 2024
2. NEJM, SURMOUNT-5 trial results (NCT05822830): Tirzepatide produced significantly greater weight loss than semaglutide at 72 weeks in a head-to-head trial
3. JAMA, SURMOUNT-4 withdrawal and weight regain data: Substantial weight regain in participants switched from tirzepatide to placebo
4. FDA, Zepbound prescribing information label: Boxed warning for thyroid C-cell tumor risk, MTC/MEN2 contraindication, and GI/gallbladder/pancreatitis safety signals
5. NEJM, SURMOUNT-1 trial results (NCT04184622): Average 20.9% body weight loss at 72 weeks on highest tirzepatide dose versus 3.1% on placebo